Newer P2Y
Clopidogrel
/ therapeutic use
Female
Heart Arrest
Hemorrhage
/ chemically induced
Humans
Male
Myocardial Infarction
/ complications
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors
/ therapeutic use
Prasugrel Hydrochloride
/ therapeutic use
Purinergic P2Y Receptor Antagonists
/ therapeutic use
Shock, Cardiogenic
/ drug therapy
Thrombosis
/ complications
Treatment Outcome
Journal
Mayo Clinic proceedings
ISSN: 1942-5546
Titre abrégé: Mayo Clin Proc
Pays: England
ID NLM: 0405543
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
21
10
2021
revised:
18
01
2022
accepted:
15
02
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
ppublish
Résumé
To evaluate the outcomes, safety, and efficacy of dual antiplatelet therapy (DAPT) with newer P2Y MEDLINE, EMBASE, and the Cochrane Library were queried systematically from inception to January 2021 for comparative studies of adults (≥18 years) with AMI-CA/CS receiving DAPT with newer P2Y Eight studies (1 randomized trial and 7 cohort studies) comprising 1100 patients (695 [63.2%] receiving clopidogrel and 405 [36.8%] receiving ticagrelor or prasugrel) were included. The population was mostly male (68.5%-86.7%). Risk of bias was low for these studies, with between-study heterogeneity and subgroup differences not statistically significant. Compared with the clopidogrel cohort, the newer P2Y In patients with AMI-CA/CS receiving DAPT, compared with clopidogrel, newer P2Y
Identifiants
pubmed: 35662424
pii: S0025-6196(22)00120-3
doi: 10.1016/j.mayocp.2022.02.016
pii:
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Purinergic P2Y Receptor Antagonists
0
Clopidogrel
A74586SNO7
Prasugrel Hydrochloride
G89JQ59I13
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1074-1085Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.